CD274 and non-small cell lung carcinoma: Based on the observation of hyperprogression in advanced non–small cell lung carcinoma (NSCLC) treated with PD-1/PD-L1 blocking antibodies, CAR-T cells directly targeting PD-L1 were generated [79].